Research Article

Decrease of Obesity by Allantoin via Imidazoline I₁-Receptor Activation in High Fat Diet-Fed Mice

Hsien-Hui Chung,1 Kung Shing Lee,2 and Juei-Tang Cheng1,3

1 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City 70101, Taiwan
2 Department of Surgery, Kaohsiung Municipal Hsiao-Kang Hospital and Kaohsiung Medical University, Kaohsiung City 81201, Taiwan
3 Institute of Medical Science, College of Health Science, Chang Jung Christian University, Guei-Ren, Tainan City 71101, Taiwan

Correspondence should be addressed to Juei-Tang Cheng; jtcchng@mail.ncku.edu.tw

Received 5 January 2013; Revised 16 February 2013; Accepted 4 March 2013

1. Introduction

Obesity is a major health problem. It is a leading cause of metabolic syndrome, and its prevalence worldwide has increased throughout the 21st century [1–3]. Obesity is associated with an increased risk of many complications, such as cardiovascular disease, type 2 diabetes, and certain types of cancer [4, 5]. Physical exercise, diet restriction, and medication are the major ways to improve obesity [6–8], but their effectiveness remains limited. Some studies have shown that certain herbal agents have antiobesity effects [9, 10]. Thus, the development of an alternative agent for the treatment of obesity is necessary.

Allantoin is known as an active ingredient in the yam (Dioscorea spp.) [11]. The yam (Dioscorea rhizome) contains ureides, including allantoin, which are used to prevent inflammation [12, 13]. The yam is a common plant that is widely used in agriculture and in the drug industry. Recently, some herbs from the Dioscoreaceae have been shown to improve the symptoms of metabolic diseases via antihyperlipidemic and antioxidative effects [14, 15]. Allantoin has been shown to activate the imidazoline I₁-receptor (I₁R) in animal models and cell lines [16]. In addition, allantoin attenuates hyperlipidemia and improves hepatic steatosis via the activation of I₁R to regulate farnesoid X receptor (FXR), demonstrating that I₁R is involved in lipid homeostasis [16]. However, the effects of allantoin on obesity remain obscure. Thus, in the present study, we investigated the effect of allantoin on obesity and the potential mechanism(s) underlying its activity.

2. Materials and Methods

2.1. Induction of Obesity in HFD-Fed Mice. Eight-week-old male C57BL/6 mice (20–25 g) obtained from the Animal Center of National Cheng Kung University Medical College were housed in a temperature-controlled room (25 ± 1°C)
under a 12:12-h light-dark cycle (light on at 06:00 h). The mice were divided into two groups. One group was fed with a standard laboratory diet (3.04 kcal/g), and the other group was fed with a high-calorie diet containing 5.16 kcal/g (TestDiet, Richmond, IN, USA) for 12 weeks to induce obesity and metabolic disorders. The db/db mice were obtained from Japan SLC, Inc. (Shizuoka, Japan). All animal procedures were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, as well as the guidelines of the Animal Welfare Act.

2.2. Measurement of Body Weight and Energy Intake. In preliminary experiments, allantoin (Sigma-Aldrich, St. Louis, MO, USA) decreased the body weight of mice fed a HFD. Its activity increased gradually and reached a stable plateau at 8 weeks. Thus, HFD-fed mice were treated with allantoin three times a day for 8 weeks, and body weight was measured at baseline (0 week) and at the 2nd, 4th, 6th, and 8th weeks of the experiment. In addition, the daily energy intake was calculated based on the consumption of normal chow (3.04 kcal/g) or HFD (5.16 kcal/g).

2.3. Measurement of Energy Intake in db/db Mice. Mice were food-deprived overnight for 12 h (8 pm–8 am). The mice were weighed and then intraperitoneally injected with either vehicle or allantoin prior to the provision of food. Each mouse was maintained isolation in a cage. The energy intake was calculated over 4 h as described previously [17].

2.4. Measurement of Epididymal White Adipose Tissues. At the end of the experimental period, the mice were sacrificed under 3% isoflurane anesthesia. The epididymal white adipose tissues (eWAT) were isolated and weighed. Then, the eWAT ratio was calculated relative to the body weight of each individual.

2.5. Immunosorbent Assay for NPY Levels. The hypothalamus was isolated from sacrificed mice, and the NPY concentration was determined. The obtained samples were homogenized at 4°C in ice-cold homogenization buffer containing 10 mM Tris-HCl (pH 7.4), 20 mM EDTA, 10 mM EGTA, 20 mM β-glycerolphosphate, 50 mM NaF, 50 mM sodium pyrophosphate, 1 mM phenylmethylsulfonyl fluoride, 25 μg/mL leupeptin, and 25 μg/mL aprotinin—protease inhibitors in a Teflon/glass homogenizer. The homogenate was centrifuged at 6000 × g for 20 min at 4°C, and the supernatant was used for NPY quantification. The NPY in each sample was measured using a commercially available mouse enzyme-linked immunosorbent assay (ELISA). According to the assay procedure, the determination of leptin in samples was performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, as well as the guidelines of the Animal Welfare Act.

2.6. Determination of Leptin Levels. The mice were fasted for 12 h and anesthetized. Blood samples were collected from the retro-orbital sinuses of each group. The blood samples were then centrifuged at 3,000 rpm for 10 min. Then, the leptin concentration was determined using enzyme-linked immunosorbent assay (ELISA). According to the assay procedure, the determination of leptin in samples was carried out using a commercially available mouse ELISA kit (Assaypro, St. Charles, MO, USA). The absorbance was measured by a SpectraMax 340PC ELISA reader (Molecular Devices Corporation, Union City, CA, USA) at 450 nm.

2.7. Histological Analysis. The epididymal white adipose tissues were removed from each group of mice and fixed in 10% formaldehyde at 4°C for 2 days. Fixed specimens were dehydrated and embedded in paraffin. The specimens were then cut into 5 μm thick sections at 50 μm intervals and stained with hematoxylin and eosin (H and E; Muto Pure Chemicals, Tokyo, Japan). The sections were observed under a light microscope.

2.8. Statistical Analysis. All values are presented as the mean ± SEM from one group of animals or samples. Analysis of variance and Dunnett’s post hoc test were used to evaluate any significant differences between groups. P < 0.05 was considered to indicate a significant difference.

3. Results
3.1. The Effect of Allantoin on Body Weight in HFD-Fed Mice. As shown in Figure 1, mice that were fed with the HFD for 3 months showed a marked (P < 0.05) increase in body weight (42.00 ± 0.34 g, n = 8) compared with the normal chow-fed mice (26.38 ± 0.44 g, n = 8). The average body weight of HFD-fed mice that received intraperitoneal...
injections of allantoin (5 mg/kg) three times a day for 8 weeks was significantly reduced compared with that of the vehicle-treated HFD-fed mice (35.38 ± 0.26 g versus 51.00 ± 0.44 g, n = 8). The allantoin-induced decrease in body weight was attenuated by the intraperitoneal injection of efaroxan at a dose (1.5 mg/kg) sufficient to block imidazoline I₁-receptors [17].

3.2. Improvement of Epididymal White Adipose Tissue (eWAT) in HFD-Fed Mice by Allantoin. As shown in Figure 2, the HFD significantly induced obesity in mice. The epididymal white adipose tissue (eWAT) cell size in HFD-fed mice was larger than that in normal chow-fed mice. Allantoin ameliorated these changes in eWAT. Pretreatment with efaroxan reversed the distribution and types of eWAT to that of the HFD group, indicating that the activity of allantoin was abolished by efaroxan (Figure 2). Allantoin also decreased the eWAT weight, and this reduction could be reversed by pretreatment with efaroxan. The eWAT ratio also exhibited the same pattern (Table 1).

3.3. The Involvement of Imidazoline I₁-Receptors in the Allantoin-Induced Reduction of Energy Intake. Intraperitoneal injection of allantoin (5 mg/kg) three times a day for 8 weeks markedly reduced the energy intake of HFD-fed mice, from 18.77 ± 1.52 kcal/g/day to 11.29 ± 0.47 kcal/g/day (Figure 3). Pretreatment with efaroxan (1.5 mg/kg, i.p.) abolished this activity. However, treatment with efaroxan alone had no influence on the energy intake of HFD-fed mice.

3.4. Changes in the Neuropeptide Y (NPY) Level in the Hypothalamus of HFD-Fed Mice. As shown in Figure 4, the hypothalamic NPY level in HFD-fed mice was markedly reduced by treatment with allantoin (5 mg/kg, i.p.) for 8 weeks. Pretreatment with efaroxan (1.5 mg/kg i.p.) 30 min before the administration of allantoin abolished this change in hypothalamic NPY (Figure 4).

3.5. Allantoin Activity in db/db Mice. As shown in Figure 5, energy intake was markedly increased in db/db mice. However, the injection of allantoin (5 mg/kg, i.p.) into db/db mice failed to produce changes in energy intake compared with vehicle-treated db/db mice. This indicates that the inhibitory
normal chow-fed group; treated HFD-fed group.

The administration of allantoin (5 mg/kg, i.p. three times per day), while another group was pretreated with efaroxan (1.5 mg/kg, i.p.) 30 min prior to the administration of allantoin.

4. Discussion

In the present study, we found that allantoin caused a marked decrease in body weight and improved eWAT accumulation and energy intake in HFD-fed mice. This antiobesity action of allantoin was reversed by I₁R blockade. These results indicate that allantoin may ameliorate HFD-induced obesity via the activation of I₁R.

Adipose tissue content is closely associated with obesity, and eWAT is widely used as an indicator in the investigation of obesity [18, 19]. In the present study, allantoin effectively decreased eWAT cell size (Figure 2) and weight (Table 1) via the activation of I₁R. This action of allantoin on eWAT is effective at a dose similar to the dose required to improve hepatic steatosis in HFD-fed mice [16]. Allantoin can thus be considered to affect lipid homeostasis via the activation of I₁R [16].

In addition to the role of adipose tissue, energy intake is also important in obesity. Some studies have indicated that imidazoline receptors exert beneficial effects on energy regulation [20, 21]. There are 3 types of imidazoline receptors, named as I₁R, I₂R and I₃R [22, 23]. Previous studies have demonstrated that the activation of I₁R may improve hypertension via sympathoinhibition [24]; the activation of I₂R may improve insulin resistance via the AMP kinase pathway to enhance glucose uptake in type-2 diabetic animal models [25–27]; and the stimulation of I₃R may stimulate insulin secretion from pancreatic β cells [28]. Although I₁R has been reported to regulate monoamine oxidase (MAO) in the brain [29], I₁R has not been found in the brain and is expressed mainly in the pancreas [28]. Thus, I₁R and I₂R seem unlikely to be involved in cerebral energy regulation. I₃R is located in mainly the rostroventrolateral medulla of the brain stem, and it has also been identified in the hypothalamus [30, 31]. The activation of I₁R has been reported to improve hypertension and hyperlipidemia [16]. Additionally, I₁R activation was shown to attenuate hyperphagia in STZ-induced diabetic mice by lowering the hypothalamic NPY level [17], similar to the mechanism observed in Zucker rats [32]. Previous studies demonstrated that appetite was reduced by an increase in blood pressure [33, 34]. However, allantoin decreases appetite at a dose that is sufficient to lower blood pressure [16].

Table 2: The inhibitory effect of allantoin on hyperleptinemia in HFD-fed mice treated with allantoin for 8 weeks. HFD-fed mice received continuous administration of allantoin (5 mg/kg, i.p. three times per day), while another group was pretreated with efaroxan (1.5 mg/kg, i.p.) 30 min prior to the administration of allantoin.

| Group                        | Leptin (ng/mL)       |
|------------------------------|----------------------|
| Normal mice                  | 18.84 ± 1.36***     |
| HFD-fed mice                 | 59.83 ± 1.05***     |
| +vehicle                     | 17.21 ± 0.82***     |
| +allantoin                   | 61.86 ± 2.25***     |

Values were obtained from each group of eight animals and expressed as the mean ± SEM. ***P < 0.001 compared with the normal chow-fed mice group; **P < 0.01 compared with the vehicle-treated HFD-fed mice group.

3.6. The Improvement of Hyperleptinemia by Allantoin in HFD-Fed Mice. The administration of allantoin (5 mg/kg, i.p., three times/daily) for 8 weeks significantly decreased the plasma leptin level in HFD-fed mice (Table 2). This decrease was attenuated by pretreatment with efaroxan (1.5 mg/kg i.p.) 30 min before the administration of allantoin.

Figure 3: The inhibitory effect of allantoin on energy intake in HFD-fed mice. Efaroxan (1.5 mg/kg) was administered 30 min before the intraperitoneal injection of allantoin (5 mg/kg). The value showed the mean ± SEM of eight animals. ***P < 0.001 compared with the normal chow-fed group; **P < 0.01 compared with the vehicle-treated HFD-fed group.

Figure 4: Changes in the hypothalamic NPY level in HFD-fed mice treated with allantoin for 8 weeks. HFD-fed mice received continuous administration of allantoin (5 mg/kg, i.p. three times per day), while another group was pretreated with efaroxan (1.5 mg/kg) 30 min before the administration of allantoin. The values are expressed as the mean ± SEM from each group of eight animals. ***P < 0.001 compared with the normal chow-fed group; **P < 0.01 compared with the vehicle-treated HFD-fed group.

Figure 4: Changes in the hypothalamic NPY level in HFD-fed mice treated with allantoin for 8 weeks. HFD-fed mice received continuous administration of allantoin (5 mg/kg, i.p. three times per day), while another group was pretreated with efaroxan (1.5 mg/kg) 30 min before the administration of allantoin. The values are expressed as the mean ± SEM from each group of eight animals. ***P < 0.001 compared with the normal chow-fed group; **P < 0.01 compared with the vehicle-treated HFD-fed group.
in HFD-fed mice via I1R activation in db/db mice, due to the absence of leptin receptor in this strain. It has been reported that leptin can inhibit NPY secretion in the hypothalamus [45]. Thus, it is reasonable to speculate that the activation of I1R by allantoin may mediate leptin to inhibit hypothalamic NPY for reduction of hyperphagia to result in the decrease of obesity. However, the regulation of hypothalamic NPY level is quite complicated, including roles for proopiomelanocortin (POMC) neurons, the alpha-melanocyte-stimulating hormone (α-MSH), and melanocortin-3 (MC3) receptors [46, 47]. Thus, the detailed mechanism of action of allantoin in HFD-induced obesity requires further investigation in the future.

5. Conclusions

We found that allantoin has antiobesity effects in HFD-fed mice and that these effects are mediated by the activation of I1R, which results in lower energy intake and reduced eWAT accumulation. Thus, allantoin can be used as an alternative agent for the improvement of obesity in the future.

Abbreviations

eWAT: Epididymal white adipose tissue
HFD: High fat diet
I1R: Imidazoline I1-receptors
IP: Intraperitoneal
NPY: Neuropeptide Y.

Authors’ Contribution

Hsien-Hui Chung and Kung Shing Lee contributed equally to this article.

Acknowledgments

The authors thank Dr. K. C. Cheng and Mr. K. F. Liu for skillful assistance with these experiments. The present study was funded mainly by a Grant from the National Sciences Council (NSC 99-2628-B309-001-MY3) of Taiwan.

References

[1] R. Hutcheson and P. Rocic, “The metabolic syndrome, oxidative stress, environment, and cardiovascular disease: the great exploration,” Experimental Diabetes Research, vol. 2012, Article ID 271028, 13 pages, 2012.
[2] C. Koebnick, N. Smith, K. Huang, M. P. Martinez, H. A. Clancy, and L. H. Kushi, “The prevalence of obesity and obesity-related health conditions in a large, multiethnic cohort of young adults in California,” Annals of Epidemiology, vol. 22, no. 9, pp. 609–616, 2012.
[3] R. Woodhouse, “Obesity in art—a brief overview,” Frontiers of Hormone Research, vol. 36, pp. 271–286, 2008.
[4] D. W. Haslam and W. P. T. James, “Obesity,” The Lancet, vol. 366, no. 9492, pp. 1197–1209, 2005.
[5] M. J. Müller, M. Lagerpusch, J. Enderle, B. Schautz, M. Heller, and A. Bosy-Westphal, “Beyond the body mass index: tracking body composition in the pathogenesis of obesity and the metabolic syndrome,” Obesity Reviews, vol. 13, supplement 2, pp. 6–13, 2012.
Evidence-Based Complementary and Alternative Medicine

[6] N. L. Novak and K. D. Brownell, "Obesity: a public health approach," The Psychiatric Clinics of North America, vol. 34, no. 4, pp. 895–909, 2011.

[7] G. Dubnov-Raz and E. M. Berry, "The dietary treatment of obesity," The Medical Clinics of North America, vol. 95, no. 5, pp. 939–952, 2011.

[8] A. J. Scheen and P. Ernst, "New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat," Diabetes and Metabolism, vol. 28, no. 6, part 1, pp. 437–445, 2002.

[9] M. L. Mollah, G. S. Kim, H. K. Moon et al., "Antibesity effects of wild ginseng (Panax ginseng C.A. meyer) mediated by PPAR-γ, GLUT4 and LPL in ob/ob mice," Phytotherapy Research, vol. 23, no. 2, pp. 220–225, 2009.

[10] N. Vasudeva, N. Yadav, and S. K. Sharma, "Natural products: a safest approach for obesity," The Chinese Journal of Integrative Medicine, vol. 18, no. 6, pp. 473–480, 2012.

[11] K. Sagara, M. Ojima, K. Suto, and T. Yoshida, "Quantitative determination of allantoin in Dioscorea rhizome and an oriental pharmaceutical preparation, Hachimi-Gan, by high-performance liquid chromatography," Planta Medica, vol. 55, no. 1, article 93, 1989.

[12] A. V. Shestopalov, T. P. Shkurat, Z. I. Mikhasinovich et al., "Biological functions of allantoin," Izvestia Akademii Nauk Serii Biologicheskaia, no. 5, pp. 541–545, 2006.

[13] M. Y. Lee, N. H. Lee, D. Jung et al., "Protective effects of allantoin against ovalbumin (OVA)-induced lung inflammation in a murine model of asthma," International Immunopharmacology, vol. 10, no. 4, pp. 474–480, 2010.

[14] W. C. Chang, Y. M. Yu, C. H. Wu, Y. H. Tseng, and K. Y. Wu, "Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome," The Canadian Journal of Physiology and Pharmacology, vol. 83, no. 5, pp. 423–430, 2005.

[15] T. Wang, R. C. Choi, J. Li et al., "Trillin, a steroid saponin isolated from the rhizomes of Dioscorea nipponica, exerts protective effects against hyperlipidemia and oxidative stress," Journal of Ethnopharmacology, vol. 139, no. 1, pp. 214–220, 2012.

[16] T. T. Yang, N. H. Chiu, H. H. Chung, C. T. Hsu, W. J. Lee, and J. T. Cheng, "Stimulatory effect of allantoin on imidazoline I receptors in animal and cell line," Hormone and Metabolic Research, vol. 44, no. 12, pp. 879–884, 2012.

[17] H. H. Chung, T. T. Yang, M. F. Chen, M. T. Chou, and J. T. Cheng, "Improvement of hyperphagia by activation of cerebral I(1)-imidazoline receptors in streptozotocin-induced diabetic mice," Hormone and Metabolic Research, vol. 44, no. 9, pp. 645–649, 2012.

[18] K. Matsumoto, Y. Watanabe, and S. I. Yokoyama, "Okara, soybean residue, prevents obesity in a diet-induced murine obesity model," Bioscience, Biotechnology and Biochemistry, vol. 71, no. 3, pp. 720–727, 2007.

[19] A. Bartolomucci, E. Bresciani, I. Bulgarelli et al., "Chronic intracerebroventricular injection of TLQP-21 prevents high fat diet induced weight gain in fast weight-gaining mice," Genes and Nutrition, vol. 4, no. 1, pp. 49–57, 2009.

[20] C. S. Niu, H. T. Wu, K. C. Cheng, K. C. Lin, C. T. Chen, and J. T. Cheng, "A novel mechanism for decreasing plasma lipid level from imidazoline I-1 receptor activation in high fat diet-fed mice," Hormone and Metabolic Research, vol. 43, no. 7, pp. 458–463, 2011.

[21] P. S. Yang, H. T. Wu, H. H. Chung et al., "Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 385, no. 1, pp. 51–56, 2012.

[22] N. V. Gongadze, N. A. Antelava, and T. D. Kezeli, "Imidazoline receptors," Georgian medical news, no. 160-161, pp. 44–47, 2008.

[23] G. A. Head and D. N. Mayorov, "Imidazoline receptors, novel agents and therapeutic potential," Cardiovascular and Hematological Agents in Medicinal Chemistry, vol. 4, no. 1, pp. 17–32, 2006.

[24] G. A. Head, S. L. Burke, and C. K. Chan, "Site and receptors involved in the sympathoinhibitory actions of rilmenidine," Journal of Hypertension, Supplement, vol. 16, no. 3, pp. S7–S12, 1998.

[25] W. C. Ko, I. M. Liu, H. H. Chung, and J. T. Cheng, "Activation of I1-imidazoline receptors may ameliorate insulin resistance in fructose-rich chow-fed rats," Neuroscience Letters, vol. 448, no. 1, pp. 90–93, 2008.

[26] C. H. Su, I. M. Liu, H. H. Chung, and J. T. Cheng, "Activation of I2-imidazoline receptors by agmatine improved insulin sensitivity through two mechanisms in type-2 diabetic rats," Neuroscience Letters, vol. 457, no. 3, pp. 125–128, 2009.

[27] T. T. Yang, P. M. Ku, C. T. Hsu, H. H. Chung, W. J. Lee, and J. T. Cheng, "Mediation of AMP kinase in the increase of glucose uptake in L6 cells induced by activation of imidazoline I-2 receptors," Hormone and Metabolic Research, 2013.

[28] N. G. Morgan and S. L. F. Chan, "Imidazoline binding sites in the endocrine pancreas: can they fulfill their potential as targets for the development of new insulin secretagogues?" Current Pharmaceutical Design, vol. 7, no. 14, pp. 1413–1431, 2001.

[29] N. J. Anderson, P. A. Lupo, D. J. Nutt, A. L. Hudson, and E. S. J. Robinson, "Characterisation of imidazoline I2 binding sites in pig brain," The European Journal of Pharmacology, vol. 519, no. 1-2, pp. 68–74, 2005.

[30] A. J. Thomas, B. O. Erokwu, B. K. Yamamoto, P. Ernsberger, O. Bishara, and K. P. Strohl, "Alterations in respiratory behavior, brain neurochemistry and receptor density induced by pharmacological suppression of sleep in the neonatal period," Developmental Brain Research, vol. 120, no. 2, pp. 181–189, 2000.

[31] J. Zhang and A. A. Abdel-Rahman, "Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (I1)-receptor-mediated hypotension," Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 3, pp. 945–952, 2005.

[32] C. Bing, P. King, L. Pickavance et al., "The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones," The British Journal of Pharmacology, vol. 127, no. 1, pp. 35–42, 1999.

[33] A. P. Makris, C. R. Rush, R. C. Frederich, and T. H. Kelly, "Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity," Appetite, vol. 42, no. 2, pp. 185–195, 2004.

[34] K. Matsumura, T. Tsuchihashi, K. Fujii, and M. Iida, "Neural regulation of blood pressure by leptin and the related peptides," Regulatory Peptides, vol. 114, no. 2-3, pp. 79–86, 2003.

[35] P. J. Wellman, "Norepinephrine and the control of food intake," Nutrition, vol. 16, no. 10, pp. 837–842, 2000.

[36] S. Stujii and G. A. Bray, "Food intake of lean and obese Zucker rats following ventricular infusions of adrenergic agonists," Brain Research, vol. 587, no. 2, pp. 226–232, 1992.

[37] L. P. Edwards, T. A. Brown-Bryan, L. McLean, and P. Ernsberger, "Pharmacological properties of the central antihypertensive..."
agent, moxonidine,” *Cardiovascular Therapeutics*, vol. 30, no. 4, pp. 199–208, 2012.

[38] V. Panfilov, A. D. Morris, R. Donnelly, M. Scemama, and J. L. Reid, “The effects of rilmenidine and atenolol on mental stress, dynamic exercise and autonomic function in mild to moderate hypertension,” *The British Journal of Clinical Pharmacology*, vol. 40, no. 6, pp. 563–569, 1995.

[39] J. H. Yu and M. S. Kim, “Molecular mechanisms of appetite regulation,” *Diabetes and Metabolism Journal*, vol. 36, no. 6, pp. 391–398, 2012.

[40] C. Gallou-Kabani, A. Vigé, M. S. Gross et al., “C57BL/6J and A/J mice fed a high-fat diet delineate components of metabolic syndrome,” *Obesity*, vol. 15, no. 8, pp. 1996–2005, 2007.

[41] E. Jéquier, “Leptin signaling, adiposity, and energy balance,” *Annals of the New York Academy of Sciences*, vol. 967, pp. 379–388, 2002.

[42] X. M. Guan, H. Yu, M. Trumbauer, E. Frazier, L. H. T. van der Ploeg, and H. Chen, “Induction of neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice,” *Neuroreport*, vol. 9, no. 15, pp. 3415–3419, 1998.

[43] S. O. Kim, S. J. Yun, and E. H. Lee, “The water extract of adlay seed (Coix lachrymajobi var. mayuen) exhibits anti-obesity effects through neuroendocrine modulation,” *The American Journal of Chinese Medicine*, vol. 35, no. 2, pp. 297–308, 2007.

[44] R. C. Davis, A. van Nas, L. W. Castellani et al., “Systems genetics of susceptibility to obesity-induced diabetes in mice,” *Physiological Genomics*, vol. 44, no. 1, pp. 1–13, 2012.

[45] S. S. Dhillon, S. A. McFadden, J. A. Chalmers, M. L. Centeno, G. L. Kim, and D. D. Belsham, “Cellular leptin resistance impairs the leptin-mediated suppression of neuropeptide Y secretion in hypothalamic neurons,” *Endocrinology*, vol. 152, no. 11, pp. 4138–4147, 2011.

[46] S. Jégou, I. Boutelet, and H. Vaudry, “Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus,” *Journal of Neuroendocrinology*, vol. 12, no. 6, pp. 501–505, 2000.

[47] H. Zheng, R. L. Townsend, A. C. Shin, L. M. Patterson, C. B. Phifer, and H. R. Berthoud, “High-fat intake induced by mu-opioid activation of the nucleus accumbens is inhibited by Y1R-blockade and MC3/4R-stimulation,” *Brain Research*, vol. 1350, pp. 131–138, 2010.